Results 221 to 230 of about 380,929 (303)

Molecular Stratification of Antiphospholipid Syndrome Through Integrative Analysis of the Whole‐Blood RNA Transcriptome

open access: yesArthritis &Rheumatology, EarlyView.
Objective Antiphospholipid syndrome (APS) is a thromboinflammatory disorder characterized by clinical and mechanistic heterogeneity that complicates early diagnosis and hinders targeted treatment. We aimed to identify distinct molecular endotypes among antiphospholipid antibody (aPL)–positive patients using whole‐blood transcriptomics.
Amala Ambati   +13 more
wiley   +1 more source

Bibliometric analysis of the trends in research on the link between gut microbiota and pancreatic cancer. [PDF]

open access: yesFront Cell Infect Microbiol
Yu Z   +6 more
europepmc   +1 more source

Interleukin‐18 Levels Are Associated With Disease Course in Patients With Still Disease Treated With Interleukin‐1 Inhibitors

open access: yesArthritis &Rheumatology, EarlyView.
Objective To evaluate the prognostic utility of circulating interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in patients with Still disease (SD) receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan   +8 more
wiley   +1 more source

Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab

open access: yesArthritis &Rheumatology, EarlyView.
Objective The objective of the study was to determine risk factors for relapse of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) after reinduction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post hoc analysis of the RITAZAREM clinical trial.
Ellen Romich   +62 more
wiley   +1 more source

Bibliometric and visual analysis of ferroptosis in cardiovascular diseases. [PDF]

open access: yesJ Cardiothorac Surg
Zhao X, Cao X, Lei L, Xu W, Guo Y, He Y.
europepmc   +1 more source

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All

open access: yes
Arthritis &Rheumatology, EarlyView.
Stephen J. Balevic   +2 more
wiley   +1 more source

Per‐ and Polyfluoroalkyl Substances and Hand Osteoarthritis: Data From the Osteoarthritis Initiative

open access: yesArthritis &Rheumatology, EarlyView.
Objective To explore whether biologic levels of specific per‐ and polyfluoroalkyl substances (PFAS) and a mixture of PFAS—reflecting the overall effect and accounting for correlations among PFAS—relate to incident hand osteoarthritis (HOA) and progression.
Jeffrey B. Driban   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy